German firm Carl Zeiss sees growing demand for eye care tech in India
The Hindu
German tech firm Carl Zeiss boosts AI-driven medical device market in India with rising DR cases & increasing diabetic population.
Carl Zeiss, a German technology firm that manufactures optical systems and optoelectronics, said India has been a booming market for its artificial intelligence (AI) driven medical devices as the country witnessed a spike in diabetic retinopathy (DR) cases in recent years.
AI in medicine was a boon in the management of diseases like DR as the technology assists in screening patients and enables early detection of symptoms, enabling timely treatment, said Dipu Bose, Head, Carl Zeiss Meditec, India & Neighbouring Markets.
Latest data from the Indian Council of Medical Research published in 2023, shows the prevalence of diabetes in India reached an alarming 10.1 crore. According to the International Diabetes Federation (IDF), in 2021, there were an estimated 77 million adults living with diabetes in the country, accounting for 1 in 7 adults worldwide who are living with diabetes. Also, DR contributed significantly to cases of blindness in the country, reported the National Programme for Control of Blindness and Visual Impairment.
“The integration of AI and diagnostic imaging promises effective management of DR,’‘ Mr. Bose said. He also claimed that “demand for Zeiss products in India has been steadily rising. As the country’s healthcare landscape modernises, innovative imaging equipment is gaining importance and our offerings including ophthalmic diagnostic tools are finding fast acceptance among leading eye-care providers in the country.”
Zeiss’ medical devices are also used for rear of an eye photography, helps in diagnosing conditions like cataracts, age-related macular degeneration, and other eye diseases.
“Our R&D centres in India employ 500 engineers and technicians. They actively contribute to the design and development of products and tools for the local and global markets,’‘ Mr. Bose added.
The ZEISS Group generated an annual revenue of more than 10 billion euros in the October-September fiscal last year with India contributing ₹1800 crore to it.
India seeks alternative sources for specialty fertilizers from Belgium, Egypt, and others due to China's export restrictions.
India and Russia commit to enhancing trade in national currencies, aiming for $100 billion bilateral trade by 2030.
Stock markets soar as RBI cuts interest rates, with Sensex rising 447 points amidst positive investor sentiment and revised growth forecasts.
AAP's Raghav Chadha calls for banning 10-minute delivery services, highlighting the harsh conditions faced by gig workers.
IndiGo flight cancellations: Follow LIVE updates from The Hindu as IndiGo's operations face issues with over 400 flights cancelled today.
DGCA grants IndiGo exemption from night-duty limits for pilots amid widespread flight cancellations and operational disruptions.
RBI to launch a two-month campaign in January 2026 to address pending grievances with the Ombudsman for improved customer service.
RBI plans ₹1 lakh crore OMO in December to boost liquidity amid upcoming tax payments, ensuring stability in the banking system.
IndiGo faces ongoing flight delays and cancellations due to technology issues, weather, and new crew rostering rules.
Stock markets experience volatility as investors await RBI's monetary policy amid foreign fund outflows and mixed global trends.
ED attaches assets worth ₹1,120 crore in Anil Ambani's Reliance Group case, totaling ₹10,000 crore amid money laundering probe.
Rupee rises 20 paise to 89.69 against the dollar as investors await RBI's monetary policy decision amidst market pressures.
Just nine Fugitive Economic Offenders (FEOs) owed Indian banks over ₹58,000 crore in principal and interest. To date, banks have recovered just over ₹19,000 crore — roughly 33% of the total dues.